Kuvan

Last updated on RxList: 3/27/2020
Kuvan Side Effects Center

What Is Kuvan?

Kuvan (saproterin dihydrochloride tablets) is a synthetic form of a natural salt that contributes to the function of a certain enzyme in the body used to help the body activate the enzyme needed to control blood levels of phenylalanine. Kuvan is used in people with phenylketonuria (PKU).

What Are Side Effects of Kuvan?

Common side effects of Kuvan include:

Dosage for Kuvan

The recommended starting dose of Kuvan is 10 mg/kg/day taken once daily.

What Drugs, Substances, or Supplements Interact with Kuvan?

Kuvan may interact with levodopa, methotrexate, sildenafil, tadalafil, or vardenafil. Tell your doctor all medications and supplements you use.

Kuvan During Pregnancy and Breastfeeding

During pregnancy, Kuvan should be used only when prescribed. It may be harmful to a fetus. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

Additional Information

Our Kuvan (saproterin dihydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Brain Food Pictures: What to Eat to Boost Focus See Slideshow
Kuvan Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives, rash; wheezing, cough, difficult breathing; nausea, feeling light-headed; flushing (warmth, redness, or tingly feeling); swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • behavior changes, seizures, or problems with speech;
  • loss of appetite, difficulty swallowing, throat pain, severe stomach discomfort or pain, nausea, vomiting;
  • bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; or
  • hyperactive behavior.

Common side effects may include:

  • headache;
  • diarrhea;
  • vomiting; or
  • runny or stuffy nose, sore throat, cough.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Kuvan (Saproterin Dihydrochloride Tablets)

QUESTION

The abbreviated term ADHD denotes the condition commonly known as: See Answer
Kuvan Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

PKU Clinical Studies

The safety of Kuvan was evaluated in 7 clinical studies in patients with PKU (aged 1 month to 50 years) [see Clinical Studies].

In Studies 1-4 (controlled and uncontrolled studies), 579 patients with PKU aged 4 to 49 years received Kuvan in doses ranging from 5 to 20 mg/kg per day for lengths of treatment ranging from 1 to 164 weeks. The patient population was evenly distributed in gender, and approximately 95% of patients were Caucasian. The most common adverse reactions (≥4% of patients) were headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion.

The data described in Table 3 reflect exposure of 74 patients with PKU to Kuvan at doses of 10 to 20 mg/kg per day for 6 to 10 weeks in two double-blind, placebo-controlled clinical trials (Studies 2 and 4).

Table 3 enumerates adverse reactions occurring in at least 4% of patients treated with Kuvan in the double-blind, placebo-controlled clinical trials described above.

Table 3: Summary of Adverse Reactions Occurring in ≥4% of Patients in Placebo-Controlled Clinical Studies with Kuvan

MedDRA Preferred TermTreatment
Kuvan
(N=74)
Placebo
(N=59)
No. Patients (%)No. Patients (%)
Headache11 (15)8 (14)
Rhinorrhea8 (11)0
Pharyngolaryngeal pain7(10)1 (2)
Diarrhea6 (8)3 (5)
Vomiting6 (8)4 (7)
Cough5 (7)3 (5)
Nasal congestion3 (4)0

In open-label, uncontrolled clinical trials (Studies 1 and 3) all patients received Kuvan in doses of 5 to 20 mg/kg per day, and adverse reactions were similar in type and frequency to those reported in the double-blind, placebo-controlled clinical trials [see Clinical Studies].

In Study 5, 65 pediatric patients with PKU aged 1 month to 6 years received Kuvan 20 mg/kg per day for 6 months. Adverse reactions in these patients were similar in frequency and type as those seen in other Kuvan clinical trials except for an increased incidence of low Phe levels. Twenty-five percent (16 out of 65) of patients developed Phe levels below normal for age [see WARNINGS AND PRECAUTIONS, Pediatric Use, and Clinical Studies].

In Study 6, a long term, open-label, extension study of 111 patients aged 4 to 50 years, receiving Kuvan in doses ranging from 5 to 20 mg/kg per day, adverse reactions were similar in type and frequency to those reported in the previous clinical studies. Fifty-five patients received Kuvan both as dissolved and intact tablets. There were no notable differences in the incidence or severity of adverse reactions between the two methods of administration. The mean (± SD) exposure to sapropterin for the entire study population was 659 ± 221 days (maximum 953 days).

In Study 7, 27 pediatric patients with PKU aged 0 to 4 years received Kuvan 10 mg/kg per day or 20 mg/kg per day. Adverse reactions were similar in type and frequency to those observed in other clinical trials, with the addition of rhinitis, which was reported in 2 subjects (7.4%).

Safety Experience From Clinical Studies For Non-PKU Indications

Approximately 800 healthy subjects and patients with disorders other than PKU, some of whom had underlying neurologic disorders or cardiovascular disease, have been administered a different formulation of the same active ingredient (sapropterin) in approximately 19 controlled and uncontrolled clinical trials. In these clinical trials, subjects were administered sapropterin at doses ranging from 1 to 100 mg/kg per day for lengths of exposure from 1 day to 2 years. Serious and severe adverse reactions (regardless of causality) during sapropterin administration were seizures, exacerbation of seizures [see WARNINGS AND PRECAUTIONS], dizziness, gastrointestinal bleeding, post-procedural bleeding, headache, irritability, myocardial infarction, overstimulation, and respiratory failure. Common adverse reactions were headache, peripheral edema, arthralgia, polyuria, agitation, dizziness, nausea, pharyngitis, abdominal pain, upper abdominal pain, and upper respiratory tract infection.

Postmarketing Experience

The following adverse reactions have been reported during post-approval use of Kuvan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions including anaphylaxis and rash: Most hypersensitivity reactions occurred within several days of initiating treatment [see WARNINGS AND PRECAUTIONS].

Gastrointestinal reactions: esophagitis, gastritis, oropharyngeal pain, pharyngitis, esophageal pain, abdominal pain, dyspepsia, nausea, and vomiting [see WARNINGS AND PRECAUTIONS].

Hyperactivity: Two cases have been reported. In one case, the patient received an accidental overdosage of Kuvan [see WARNINGS AND PRECAUTIONS, OVERDOSAGE].

Read the entire FDA prescribing information for Kuvan (Saproterin Dihydrochloride Tablets)

© Kuvan Patient Information is supplied by Cerner Multum, Inc. and Kuvan Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors